AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago
The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
As a result, Imago will become a subsidiary of Merck.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)